Published On: Tue, Sep 4th, 2018

Evox Therapeutics raises £35.5m to advance exosome therapeutics

Tagged with: | | | | | | | | |

Evox Therapeutics, an biotech spinout focused on developing exosome therapeutics, has raised £35.5 million from a Series B financing round led by Redmile Group with new investments from Google’s GV, Cowen Healthcare Investments and others.

The Series B round of the UK biotechnology company also saw participation from existing investors – Oxford Sciences Innovation (OSI) and . Previously, Evox Therapeutics raised £10 million from Oxford Sciences Innovation as part of a Series A seed financing round.

The UK biotechnology company said that the new capital will be used for advancing its exosome-based therapeutics pipeline, including progression of various rare assets towards the clinical stage, and continued development of its exosome drug platform.

Jeremy Green – Founder & Portfolio Manager of Redmile Group, said: “We believe exosomes represent an important emerging therapeutic approach with potentially broad applicability, and we are enthusiastic to partner with the Evox team.”

Evox Therapeutics said that it is modifying exosomes, the natural vesicular delivery system in the human body to enable a range of to reach tissues and compartments that in the past were difficult to reach. Included in these are crossing the blood brain barrier to make drugs reach the central nervous system, extra-hepatic delivery of RNA therapeutics, and intracellular delivery of biologics.

Evox Therapeutics is developing exosome-based therapeutics.

Evox Therapeutics is developing exosome-based therapeutics. Photo courtesy of Daino_16/

– CEO of Evox Therapeutics, said: “Over the past several years we have continued to expand the reach of our exosome platform, translating that knowledge into impactful therapeutics for our internal pipeline and for partners.

“We have also vigorously expanded our robust intellectual property portfolio, built our internal R&D teams, and put in place advisory boards who are offering deep insights as we advance key programmes towards clinical development.

“We are excited by the inherent transformational potential of our exosome technology, which significantly improves and enables the delivery of a wide range of therapeutic molecules, including antibodies, proteins, nucleic acids, and small molecules.

“This additional funding will enable us to advance our pipeline of novel exosome-based therapeutics towards the clinic and allow continued expansion of our world-leading exosome platform.”

The UK biotechnology company is developing its own pipeline of exosome-based treatments for rare, life-threatening diseases with significant unmet need.

It is also looking to enter into partnerships with major pharma companies to fully exploit the use of exosome-based therapeutics for the of a range of other diseases.

Related posts